President Trump's order and Eli Lilly's investment signal interest in psychedelics, not scientific validation.

Long-term durability of psychedelics, safety for patients, and therapy protocols remain understudied.

Acceleration should cut red tape, not lower evidence standards.

It is yet unclear if benefits come from psychedelics themselves, therapy, the setting, or some combination.

"You shall know the truth, and the truth shall make you mad." —Aldous Huxley

In the span of three months, psychedelic medicine crossed two important thresholds.

In April, President Donald Trump signed an executive order making it federal policy to accelerate psychedelic research and “appropriate drug approvals” for serious mental illness. Then, in July, Eli Lilly agreed to acquire AtaiBeckley, a biotechnology company developing psychedelic and psychedelic-derived treatments.

These developments are understandably being read as validation of the field. But they validate two things more clearly than they validate the medicines themselves: that the federal government wants development to move faster, and that a major pharmaceutical company believes the commercial opportunity is substantial.

Neither political commitment nor market valuation is a scientific verdict.

That distinction matters because psychedelic therapies may indeed become important treatments. Patients with treatment-resistant depression, post-traumatic stress disorder, substance-use disorders, and other disabling illnesses urgently need better options. The current evidence contains credible signals of benefit, and those signals justify serious investment and accelerated research.

But urgency is not the same as haste. The American Psychiatric Association, while welcoming federal support for research, responded to the executive order by emphasizing that the scientific evidence remains inadequate to endorse psychedelic treatments for psychiatric disorders outside approved investigational studies. It called for trained clinicians, controlled settings, and the same scientific and ethical standards applied to other promising medicines.

The central problem is not that psychedelic drugs have been........

© Psychology Today